Agenus Inc. (NASDAQ:AGEN) Given Consensus Recommendation of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has earned an average recommendation of “Hold” from the five analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $14.50.

Several research analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating on shares of Agenus in a report on Monday, October 20th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Agenus in a research report on Monday, December 29th.

Agenus Stock Down 0.3%

Agenus stock opened at $2.89 on Thursday. The company has a fifty day simple moving average of $3.59 and a 200-day simple moving average of $4.17. The firm has a market capitalization of $98.29 million, a price-to-earnings ratio of -1.36 and a beta of 1.62. Agenus has a 52-week low of $1.38 and a 52-week high of $7.34.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, November 10th. The biotechnology company reported $1.94 earnings per share for the quarter, missing analysts’ consensus estimates of $2.63 by ($0.69). The company had revenue of $30.24 million for the quarter, compared to analysts’ expectations of $80.39 million. On average, research analysts anticipate that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in Agenus during the first quarter worth about $88,000. AQR Capital Management LLC grew its stake in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares during the period. Acadian Asset Management LLC acquired a new stake in shares of Agenus during the 1st quarter worth approximately $58,000. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Agenus during the 2nd quarter valued at approximately $85,000. Finally, CWM LLC raised its position in shares of Agenus by 105.8% during the 2nd quarter. CWM LLC now owns 26,246 shares of the biotechnology company’s stock valued at $120,000 after buying an additional 13,494 shares during the period. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.